Safety of MDCK cell culture-based influenza vaccines (Q30400326)

21 June 2017

1 reference

title

Safety of MDCK cell culture-based influenza vaccines (English)

1 reference

21 June 2017

1 reference

2

Heinz-Josef Schmitt

1 reference

21 June 2017

3

Heidi Trusheim

1 reference

21 June 2017

1

Jens-Peter Gregersen

1 reference

21 June 2017

Michael Bröker

4

1 reference

21 June 2017

publication date

1 February 2011

1 reference

21 June 2017

number of pages

10

1 reference

based on heuristic

inferred from page(s)

published in

Future Microbiology

1 reference

21 June 2017

volume

6

1 reference

21 June 2017

issue

2

1 reference

21 June 2017

page(s)

143-152

1 reference

Subtypes of Madin-Darby canine kidney (MDCK) cells defined by immunocytochemistry: further evidence for properties of renal collecting duct cells

21 June 2017

cites work

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.161

Cloning and assessment of tumorigenicity and oncogenicity of a Madin-Darby canine kidney (MDCK) cell line for influenza vaccine production

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.161

Current challenges in implementing cell-derived influenza vaccines: implications for production and regulation, July 2007, NIBSC, Potters Bar, UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.161

Evidence for host-cell selection of influenza virus antigenic variants

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.161

Efficacy of inactivated influenza A virus (H3N2) vaccines grown in mammalian cells or embryonated eggs

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.161

A quantitative risk assessment of exposure to adventitious agents in a cell culture-derived subunit influenza vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.161

Validation of the safety of MDCK cells as a substrate for the production of a cell-derived influenza vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.161

Use of MDCK cells for production of live attenuated influenza vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.161

A probabilistic model for risk assessment of residual host cell DNA in biological products

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.161

A risk-assessment model to rate the occurrence and relevance of adventitious agents in the production of influenza vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.161

Canine MDCK cell lines are refractory to infection with human and mouse prions

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.161

Safety and immunogenicity of a novel influenza subunit vaccine produced in mammalian cell culture.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.161

Clinical Efficacy of Cell Culture–Derived and Egg‐Derived Inactivated Subunit Influenza Vaccines in Healthy Adults

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.161

Vaccine production capacity for seasonal and pandemic (H1N1) 2009 influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.161

21 January 2018

Identifiers

DOI

10.2217/FMB.10.161

1 reference

21 June 2017

1 reference